RTI-371
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H25ClN2O |
| Molar mass | 392.93 g·mol−1 |
| 3D model (JSmol) | |
| |
 N Y (what is this?) (verify) | |
3β-(4-Methylphenyl)-2β-[3-(4-chlorophenyl)isoxazol-5-yl]tropane (RTI-4229-371) is a phenyltropane derived drug which acts as a potent and selective dopamine reuptake inhibitor in vitro, yet unusually for this class of compound, both RTI-371 and the closely related compound RTI-370 failed to produce locomotor stimulation in mice. In addition to this, in drug substitution tests RTI-370 weakly generalized to cocaine whereas RTI-371 did not generalize at all.
This phenomenon has also been observed for other dopamine reuptake inhibitors from other classes. It may be caused by lack of BBB penetration, or interactions at alternative receptor sites.[1][2]
References
- ↑ Navarro HA, Howard JL, Pollard GT, Carroll FI (April 2009). "Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter". British Journal of Pharmacology. 156 (7): 1178–84. doi:10.1111/j.1476-5381.2009.00124.x. PMC 2697692. PMID 19226282.
- ↑ Foster MD (2011). Computational study of RTI-371, a positive allosteric modulator of the cannabinoid CB1 receptor (PDF) (MSc thesis). The University of North Carolina at Greensboro.
| 2-Carboxymethyl Esters | |
|---|---|
| (3,4-Disubstituted Phenyl)-tropanes | |
| Arylcarboxy | |
| Carboxyalkyl | |
| Acyl | |
| β,α Stereochemistry | |
| α,β Stereochemistry | |
| Heterocycles: 3-Substituted-isoxazol-5-yl | |
| Heterocycles: 3-Substituted-1,2,4-oxadiazole | |
| N-alkyl | |
| N-replaced (S,O,C) | |
| Irreversible | |
| Nortropanes (N-demethylated) | |
| D1-like |
| ||||||
|---|---|---|---|---|---|---|---|
| D2-like |
| ||||||